- EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)Cheng, Y.; Liu, Y.; Zhang, W.; Wu, L.; Zhou, C.; Wang, D.; Xia, B.; Bi, M.; Fu, X.; Li, C.; Chen, G.; Lv, D.; Zhao, Y.; Huang, J.; Li, M.; Yi, T.; Huang, X.; Yang, R.; Chen, Z.; Wang, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancerZhou, Chengzhi; Liu, Ming; Qiu, Guihuan; Xie, Xiaohong; Lin, Xinqing; Guan, Wenhui; Xie, Zhanhong; Zhang, Jiexia; Qin, Yinyin; Du, Haijian; Chen, XinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory researchZhao, Y.; Liu, J.; Li, X.; Li, Y.; Pu, H.; Wang, X.; Yang, M.; Bai, S.; Guo, L.; Zhao, L.; Zhang, M.; Zhao, H.; Xu, S.; Wang, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC)
13阅读
